Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, double-blind, adaptive platform clinical trial ...

Research suggests that it is important for clinicians to identify the risk for ILD in patients with SSc so that therapy can be initiated.

A nationwide Swedish register-based study revealed that individuals with systemic sclerosis had a higher risk for hematologic malignancies. Myeloid malignancies typically presented around disease ...

Preclinical data showed promise in both systemic sclerosis bleomycin-induced mouse models and in patient-derived skin fibroblasts treated with EYD-001. The Food and Drug Administration (FDA) has ...

Systemic sclerosis is a complex autoimmune condition marked by aberrant immune activation, widespread fibrosis and vasculopathy that affect the skin and multiple internal organs. The disease manifests ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Clinicians managing systemic sclerosis should focus on treating “what is treatable” in each organ ...

Please provide your email address to receive an email when new articles are posted on . Risks were particularly high in women who received both systemic and local hormone therapies. Future studies ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of ...

New-onset interstitial lung disease can be detected up to 10 years after initial negative screening in patients with systemic sclerosis, with a higher mortality risk vs those without lung involvement.

The VEDOSS project has previously shown that 70% of patients with Raynaud's phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on ...